Form 4: EyePoint Pharmaceuticals Director Nancy Lurker Reports Stock Transactions
SEC Form 4
Director Nancy Lurker reports the vesting of restricted stock units and subsequent acquisition of common stock, along with holdings in a family trust.
Summary
- On February 9, 2025, Nancy Lurker, a director of EyePoint Pharmaceuticals, reported a transaction involving restricted stock units.
- 20,000 restricted stock units vested, converting into 20,000 shares of common stock.
- The transaction was executed under Transaction Code M.
- Following the transaction, Lurker directly owns 205,436 shares of common stock.
- Lurker also has indirect ownership of 126,889 shares through a family trust.
- The restricted stock units vest in three annual installments beginning February 9, 2023.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company director, neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| February 9, 2023 | Start date for the three annual installments of restricted stock units vesting. |
| February 9, 2025 | Date of transaction: vesting of restricted stock units and acquisition of common stock. |
| February 11, 2025 | Date of report filing. |
Keywords
EyePoint Pharmaceuticals, Director, Stock Transaction, Form 4, Beneficial Ownership, Restricted Stock Units, Common Stock, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.